EZH2 and acute myeloid leukemia: In support of EZH2 as a target for DZNep is our observation that replacement of this analogue by the specific inhibitor of EZH2, GSK-126 [27], provides similar results with respect to its interaction with 5-AZA-CdR on AML cells (Figure 7A).